34 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
be substantially harmed;
The inability to obtain supply of the materials for our product candidate would materially and adversely affect our business … sufficient quantities of our products candidates or receive raw materials in a timely manner, we could be required to delay our ongoing clinical trials
10-K
2022 FY
EX-10.20
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
with true and complete copies of all documents, certificates, office actions, responses, correspondence, and other filings and materials related
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
) of the Exchange Act; provided, however, the Company shall not be required to deliver to the Trustee any correspondence filed with the Commission or any materials
6-K/A
OBSVF
ObsEva SA
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
.
The following materials from this Report on Form
6-K/A
are formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Unaudited Condensed
6-K
EX-99.3
nmqp y5go8bvrb8scx2e
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K/A
EX-99.2
2d5524rma8 ynt
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
otuxxj 2ian
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-10.1
l8mgmdqmtan7ze0ox
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-1.1
hvog j2djglal8nfmcg
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
c7d23
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
nc9cnqw67i4wgd 3wvgr
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
6ly8xftbiyxkhy
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am